News & Events

• September 23, 2019
  Development of a disease progression model for leucine-rich repeat kinase 2 in Parkinson’s disease to inform clinical trial designs

• September 20, 2019
  The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease

  Diane Stephensona,∗, Derek Hillb, Jesse M. Cedarbaumc, Maria Tomed, Spiros Vamvakasd, Klaus Romeroa, Daniela J. Conradoa, David T. Dextere, John Seibylf, Danna Jenningsg, Timothy Nicholash, Dawn Matthewsi, Zhiyong Xieh, Syed Imamp, Paul Maguirej, David Russellf, Mark Forrest Gordonk, Glenn T. Stebbinso, Ed Somerl, Jill Gallaghere, Arthur Roache, Peter Bassechesm, Donald Grossetn and Kenneth Marekf on behalf of the Critical Path for Parkinson’s Consortium

• June 24, 2019
  The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease

• May 24, 2019
  Molecular Neuroimaging of the Dopamine Transporter (DAT) as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson Disease

• October 10, 2018
  New Frontiers in Parkinson’s Disease: From Genetics to The Clinic